REGN21353
/ Regeneron
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 01, 2026
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
(clinicaltrials.gov)
- P1/2 | N=192 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals
New P1/2 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1